AGL 34.48 Decreased By ▼ -0.72 (-2.05%)
AIRLINK 132.50 Increased By ▲ 9.27 (7.52%)
BOP 5.16 Increased By ▲ 0.12 (2.38%)
CNERGY 3.83 Decreased By ▼ -0.08 (-2.05%)
DCL 8.10 Decreased By ▼ -0.05 (-0.61%)
DFML 45.30 Increased By ▲ 1.08 (2.44%)
DGKC 75.90 Increased By ▲ 1.55 (2.08%)
FCCL 24.85 Increased By ▲ 0.38 (1.55%)
FFBL 44.18 Decreased By ▼ -4.02 (-8.34%)
FFL 8.80 Increased By ▲ 0.02 (0.23%)
HUBC 144.00 Decreased By ▼ -1.85 (-1.27%)
HUMNL 10.52 Decreased By ▼ -0.33 (-3.04%)
KEL 4.00 No Change ▼ 0.00 (0%)
KOSM 7.74 Decreased By ▼ -0.26 (-3.25%)
MLCF 33.25 Increased By ▲ 0.45 (1.37%)
NBP 56.50 Decreased By ▼ -0.65 (-1.14%)
OGDC 141.00 Decreased By ▼ -4.35 (-2.99%)
PAEL 25.70 Decreased By ▼ -0.05 (-0.19%)
PIBTL 5.74 Decreased By ▼ -0.02 (-0.35%)
PPL 112.74 Decreased By ▼ -4.06 (-3.48%)
PRL 24.08 Increased By ▲ 0.08 (0.33%)
PTC 11.19 Increased By ▲ 0.14 (1.27%)
SEARL 58.50 Increased By ▲ 0.09 (0.15%)
TELE 7.42 Decreased By ▼ -0.07 (-0.93%)
TOMCL 41.00 Decreased By ▼ -0.10 (-0.24%)
TPLP 8.23 Decreased By ▼ -0.08 (-0.96%)
TREET 15.14 Decreased By ▼ -0.06 (-0.39%)
TRG 56.10 Increased By ▲ 0.90 (1.63%)
UNITY 27.70 Decreased By ▼ -0.15 (-0.54%)
WTL 1.31 Decreased By ▼ -0.03 (-2.24%)
BR100 8,615 Increased By 43.5 (0.51%)
BR30 26,900 Decreased By -375.9 (-1.38%)
KSE100 82,074 Increased By 615.2 (0.76%)
KSE30 26,034 Increased By 234.5 (0.91%)

A stem-cell repair technique that has already been used to fix hundreds of injured race horses is to be tested for the first time in people with damaged Achilles tendons. Privately owned British biotech firm MedCell Bioscience Ltd said on April 15 it would start clinical tests within 12 months and planned to run a larger confirmatory study at several European hospitals in 2011.
Patients will receive injections containing millions of their own stem cells, which have been extracted and multiplied up in a laboratory, and can regenerate new tissue to repair damaged regions.
More than 1,500 race horses have been treated using the same process and follow-up data suggests a 50 percent reduction in re-injury over a three year period, compared with conventional treatment. "The move from clinical veterinary to human medicine is inspiring and unusual - we normally see the translation happening the other way around," said Nicola Maffulli, an orthopaedic surgeon and leading expert in sports medicine, who will help conduct the trial.
Stem cell therapy has become the odds-on favourite for tackling tendon damage in the world of horse racing, where tendon damage to animals which can be worth millions of dollars is all too common. The repair technique was pioneered by surgeons at the Royal Veterinary College north of London, who helped set up MedCell as a spin-out company.

Copyright Reuters, 2009

Comments

Comments are closed.